GlaxoSmithKline replaced roughly 50 of the 125 top managers, including the company's former CEO, since Emma Walmsley began in her role as head of the company last April. She said the restructuring represents an effort to increase diversity within the team and bring new ideas and skills to Glaxo's workforce, Bloomberg reports.
In restructuring roughly 40 percent of the company's leadership, Ms. Walmsley hired people outside the company from various corporations, including Google and Novartis AG, and promoted select individuals from within, the London-based company said in an email to Bloomberg.
Ms. Walmsley said in July Glaxo must focus on developing treatments for respiratory conditions, HIV, and infectious and autoimmune disorders, as well as end or divest roughly 30 drug-development programs to spur long-term growth, according to the report.